Symbols / PRLD Stock $4.27 -2.73% Prelude Therapeutics Incorporated

Healthcare • Biotechnology • United States • NMS
PRLD (Stock) Chart
O: — H: — L: — C: — V: —
SMA 20: — SMA 50: — SMA 200: —
Stock Fundamentals
Scroll to Statements
Index EQUITY
Sector Healthcare
Industry Biotechnology
CEO Dr. Krishna Vaddi D.V.M., Ph.D.
Exch · Country NMS · United States
Market Cap 268.43M
Enterprise Value 267.00M
Income -99.50M
Sales 12.14M
FCF (ttm) -23.87M
Book/sh 0.83
Cash/sh 1.25
Employees 79
Insider 10d —
IPO Sep 25, 2020
Div forward ($/yr)
Div TTM ($/yr)
Dividend Yield
Ex-Div Date
5Y Avg Yield
Yield vs 5Y Avg
Payout 0.00%
P/E —
Forward P/E -3.73
PEG —
P/S 22.11
P/B 5.13
P/C —
EV/EBITDA -2.63
EV/Sales 21.99
Quick Ratio 1.95
Current Ratio 1.99
Debt/Eq 25.92
LT Debt/Eq —
EPS (ttm) -1.29
EPS next Y -1.15
EPS Growth —
Revenue Growth 41.00%
EPS Gr Q/Q —
Rev Gr Q/Q —
Earnings (next) 2026-05-13
Earnings (prior) 2026-03-10
ROA -40.74%
ROE -99.45%
ROIC —
Gross Margin 100.00%
Oper. Margin -284.54%
Profit Margin 0.00%
Shs Outstand 43.77M
Shs Float 29.09M
Insider Own 7.65%
Instit Own 44.47%
Short Float 15.07%
Short Ratio 7.16
Short Interest 1.81M
52W High 5.54
vs 52W High -22.92%
52W Low 0.73
vs 52W Low 484.93%
Beta 0.71
Impl. Vol. 12.50%
Rel Volume 1.31
Avg Volume 344.75K
Volume 453.10K
Target (mean) $6.17
Tgt Median $6.00
Tgt Low $4.50
Tgt High $8.00
# Analysts 3
Recom Strong_buy
Prev Close $4.39
Price $4.27
Change -2.73%
About

Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing JAK2V617F, a driver mutation product for the treatment of myeloproliferative neoplasms, myelofibrosis (MF), polycythemia vera, and essential thrombocythemia (ET); KAT6A for the treatment of advanced breast cancer and other solid tumors; and mutated calreticulin degrader antibody conjugates to treat MF and ET. The company has collaboration with AbCellera Biologics to discover, develop, and commercialize novel degrader antibody conjugates. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.

Valuation Models

Price estimates from analyst targets and simple models.

1. Analyst consensus
$6.17
Mean price target
2. Current target
$4.27
Latest analyst target
3. DCF / Fair value
$-9.82
Simplified: (Free Cash Flow ÷ Shares) × 18 (P/FCF multiple). Not a …
Ratings
Current target
$4.27
Low
$4.50
High
$8.00
Mean
$6.17

Latest analyst rating changes

Date Action Analyst Rating Change Price Target
2026-04-27 main HC Wainwright & Co. Buy → Buy $8
2026-03-11 main Citizens Market Outperform → Market Outperform $6
2025-09-23 reit HC Wainwright & Co. Buy → Buy $5
2025-08-18 main JMP Securities Market Outperform → Market Outperform $3
2025-05-05 reit HC Wainwright & Co. Buy → Buy $5
2025-04-29 reit JMP Securities Market Outperform → Market Outperform $4
2025-04-08 reit HC Wainwright & Co. Buy → Buy $5
2025-03-12 reit Citizens Capital Markets Market Outperform → Market Outperform $4
2024-12-11 reit JMP Securities Market Outperform → Market Outperform $4
2024-11-08 reit HC Wainwright & Co. Buy → Buy $5
2024-10-28 reit HC Wainwright & Co. Buy → Buy $5
2024-09-19 up HC Wainwright & Co. Neutral → Buy $5
2024-09-16 reit JMP Securities Market Outperform → Market Outperform $7
2024-09-16 reit HC Wainwright & Co. Neutral → Neutral $5
2024-09-10 reit HC Wainwright & Co. Neutral → Neutral $5
2024-08-15 reit HC Wainwright & Co. Neutral → Neutral $5
2024-03-13 init JMP Securities — → Market Outperform $7
2024-02-20 down HC Wainwright & Co. Buy → Neutral $5
2023-12-19 down Morgan Stanley Equal-Weight → Underweight $4
2023-11-07 main HC Wainwright & Co. Buy → Buy $5
News
RSS: Latest PRLD news
Insider Transactions
Filed Date Insider Relationship Transaction Shares Price Value SEC
2026-04-21 BONITA DAVID P. M.D. Director and Beneficial Owner of more than 10% of a Class of Security — 2,815,315 $4.44 $12,499,999
2026-04-21 ORBIMED ADVISORS, L.L.C. Beneficial Owner of more than 10% of a Class of Security — 2,815,315 $4.44 $12,499,999
2025-10-03 HUANG JANE President — 9,375 — —
2025-07-03 HUANG JANE President — 9,375 — —
2025-04-04 HUANG JANE President — 9,375 — —
2025-03-25 VADDI KRISHNA Chief Executive Officer — 675,000 $0.69 $467,438
2025-03-25 COMBS ANDREW P Officer — 100,000 $0.69 $69,250
2025-03-21 VADDI KRISHNA Chief Executive Officer — 20,416 $0.73 $14,909
2025-03-17 VADDI KRISHNA Chief Executive Officer — 39,105 $0.75 $29,460
2025-03-13 VADDI KRISHNA Chief Executive Officer — 97,500 $0.71 $69,564
Financials
Statement View
Amounts in millions (2 decimals, no suffix) • EPS per share (2 decimals) • Trend = period evolution • YoY Growth = previous period %
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Total Revenue
12.14
+73.43%
7.00
0.00
0.00
Operating Revenue
12.14
+73.43%
7.00
0.00
0.00
Operating Expense
116.71
-20.45%
146.71
+10.91%
132.28
+7.07%
123.54
Research And Development
94.30
-20.08%
118.00
+14.12%
103.39
+11.31%
92.89
Selling General And Administration
22.41
-21.98%
28.72
-0.57%
28.88
-5.76%
30.65
General And Administrative Expense
22.41
-21.98%
28.72
-0.57%
28.88
-5.76%
30.65
Other Gand A
22.41
-21.98%
28.72
-0.57%
28.88
-5.76%
30.65
Total Expenses
116.71
-20.45%
146.71
+10.91%
132.28
+7.07%
123.54
Operating Income
-104.57
+25.16%
-139.71
-5.62%
-132.28
-7.07%
-123.54
Total Operating Income As Reported
-104.57
+25.16%
-139.71
-5.62%
-132.28
-7.07%
-123.54
EBITDA
-102.86
+25.44%
-137.94
-5.21%
-131.11
-7.28%
-122.22
Normalized EBITDA
-102.86
+25.44%
-137.94
-5.21%
-131.11
-7.28%
-122.22
Reconciled Depreciation
1.71
-3.44%
1.77
+51.58%
1.17
-11.71%
1.32
EBIT
-104.57
+25.16%
-139.71
-5.62%
-132.28
-7.07%
-123.54
Net Income
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Pretax Income
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Other Income Expense
5.07
-59.59%
12.54
+20.07%
10.45
+28.92%
8.10
Other Non Operating Income Expenses
5.07
-59.59%
12.54
+20.07%
10.45
+28.92%
8.10
Tax Rate For Calcs
0.00
0.00
0.00
0.00
Tax Effect Of Unusual Items
0.00
0.00
0.00
0.00
Net Income Including Noncontrolling Interests
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Net Income From Continuing Operation Net Minority Interest
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Net Income From Continuing And Discontinued Operation
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Net Income Continuous Operations
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Normalized Income
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Net Income Common Stockholders
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Diluted EPS
—
-1.68
+16.83%
-2.02
+17.21%
-2.44
Basic EPS
—
-1.68
+16.83%
-2.02
+17.21%
-2.44
Basic Average Shares
—
75.81
+25.60%
60.36
+27.41%
47.37
Diluted Average Shares
—
75.81
+25.60%
60.36
+27.41%
47.37
Diluted NI Availto Com Stockholders
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Line Item Trend 2023-12-31
Total Assets
277.67
Current Assets
235.59
Cash Cash Equivalents And Short Term Investments
232.94
Cash And Cash Equivalents
25.29
Other Short Term Investments
207.64
Prepaid Assets
—
Other Current Assets
2.65
Total Non Current Assets
42.08
Net PPE
37.74
Gross PPE
41.30
Accumulated Depreciation
-3.57
Properties
0.00
Machinery Furniture Equipment
2.33
Construction In Progress
0.34
Other Properties
37.05
Leases
1.58
Other Non Current Assets
4.34
Total Liabilities Net Minority Interest
40.58
Current Liabilities
21.83
Payables And Accrued Expenses
10.25
Payables
4.58
Accounts Payable
4.58
Current Accrued Expenses
5.67
Pensionand Other Post Retirement Benefit Plans Current
9.16
Current Debt And Capital Lease Obligation
1.48
Current Capital Lease Obligation
1.48
Current Deferred Liabilities
—
Current Deferred Revenue
—
Other Current Liabilities
0.94
Total Non Current Liabilities Net Minority Interest
18.75
Long Term Debt And Capital Lease Obligation
15.41
Long Term Capital Lease Obligation
15.41
Non Current Deferred Liabilities
—
Non Current Deferred Revenue
—
Other Non Current Liabilities
3.34
Stockholders Equity
237.09
Common Stock Equity
237.09
Capital Stock
0.01
Common Stock
0.01
Share Issued
54.91
Ordinary Shares Number
54.91
Treasury Shares Number
0.00
Additional Paid In Capital
693.25
Retained Earnings
-456.39
Gains Losses Not Affecting Retained Earnings
0.22
Other Equity Adjustments
0.22
Total Equity Gross Minority Interest
237.09
Total Capitalization
237.09
Working Capital
213.76
Invested Capital
237.09
Total Debt
16.89
Capital Lease Obligations
16.89
Net Tangible Assets
237.09
Tangible Book Value
237.09
Line Item Trend 2025-12-31 2024-12-31 2023-12-31 2022-12-31
Operating Cash Flow
-56.30
+45.28%
-102.89
+3.90%
-107.06
-27.87%
-83.73
Cash Flow From Continuing Operating Activities
-56.30
+45.28%
-102.89
+3.90%
-107.06
-27.87%
-83.73
Net Income From Continuing Operations
-99.50
+21.76%
-127.17
-4.38%
-121.83
-5.54%
-115.44
Depreciation Amortization Depletion
1.71
-3.44%
1.77
+51.58%
1.17
-11.71%
1.32
Depreciation And Amortization
1.71
-3.44%
1.77
+51.58%
1.17
-11.71%
1.32
Other Non Cash Items
1.53
-3.58%
1.59
-17.82%
1.94
+12.69%
1.72
Stock Based Compensation
11.91
-44.19%
21.34
-16.67%
25.62
+1.88%
25.14
Gain Loss On Sale Of PPE
—
—
—
—
Change In Working Capital
28.41
+573.84%
4.22
+140.23%
-10.48
-1224.36%
0.93
Change In Prepaid Assets
-0.20
-129.49%
0.67
+107.34%
-9.11
-136.98%
-3.84
Change In Payables And Accrued Expense
-6.90
-376.25%
2.50
+890.87%
0.25
-96.11%
6.49
Change In Accrued Expense
-2.98
-268.81%
-0.81
-132.04%
2.52
-63.09%
6.83
Change In Payable
-3.92
-218.55%
3.31
+245.59%
-2.27
-554.18%
-0.35
Change In Account Payable
-3.92
-218.55%
3.31
+245.59%
-2.27
-554.18%
-0.35
Change In Other Working Capital
35.53
—
—
—
Change In Other Current Liabilities
-0.03
-102.66%
1.05
+164.72%
-1.62
+5.08%
-1.71
Investing Cash Flow
53.46
-40.73%
90.19
+360.32%
-34.65
-142.41%
81.69
Cash Flow From Continuing Investing Activities
53.46
-40.73%
90.19
+360.32%
-34.65
-142.41%
81.69
Net PPE Purchase And Sale
-0.07
+91.23%
-0.76
+78.25%
-3.51
-16.36%
-3.02
Purchase Of PPE
-0.07
+91.23%
-0.76
+78.25%
-3.51
-16.36%
-3.02
Capital Expenditure
-0.07
+91.23%
-0.76
+78.25%
-3.51
-16.36%
-3.02
Net Investment Purchase And Sale
53.53
-41.15%
90.95
+392.15%
-31.13
-136.75%
84.71
Purchase Of Investment
-100.87
-91.42%
-52.69
+76.22%
-221.63
-85.90%
-119.22
Sale Of Investment
154.39
+7.48%
143.65
-24.59%
190.50
-6.59%
203.93
Financing Cash Flow
24.82
+20780.00%
-0.12
-100.09%
136.40
+16635.58%
0.81
Cash Flow From Continuing Financing Activities
24.82
+20780.00%
-0.12
-100.09%
136.40
+16635.58%
0.81
Net Issuance Payments Of Debt
-0.21
+47.34%
-0.40
0.00
—
Repayment Of Debt
-0.21
+47.34%
-0.40
0.00
—
Long Term Debt Payments
-0.21
+47.34%
-0.40
0.00
—
Net Long Term Debt Issuance
-0.21
+47.34%
-0.40
0.00
—
Net Common Stock Issuance
24.88
0.00
-100.00%
135.73
0.00
Proceeds From Stock Option Exercised
0.17
-62.19%
0.44
-35.54%
0.68
-16.44%
0.81
Net Other Financing Charges
-0.02
+89.63%
-0.16
-864.71%
-0.02
—
Changes In Cash
21.97
+271.44%
-12.82
-141.19%
-5.31
-334.51%
-1.22
Beginning Cash Position
16.52
-43.69%
29.34
-15.34%
34.65
-3.41%
35.87
End Cash Position
38.49
+133.02%
16.52
-43.69%
29.34
-15.34%
34.65
Free Cash Flow
-56.37
+45.62%
-103.65
+6.26%
-110.58
-27.47%
-86.75
Amortization Of Securities
-0.37
+92.00%
-4.64
-33.57%
-3.47
-234.04%
2.59
Common Stock Issuance
24.88
0.00
-100.00%
135.73
0.00
Issuance Of Capital Stock
24.88
0.00
-100.00%
135.73
0.00
Net Preferred Stock Issuance
—
—
—
—
Preferred Stock Issuance
—
—
—
—
SEC Filings

Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.

Trades
Date User Broker Pattern Type Position Size Entry Price Trade P&L Status
Posts
Published Title Author Category